You guys might want to check out Exact Sciences (EXAS) at $1.70 per share given that SQNM tried to buy them out on the cheap a couple of months ago because it looked as though SQNM was "trampling" on Exact's patent portfolio for invitro testing.
EXAS turned down SQNM's $1.50 per share offer back in January and instead, welcomed a strategic $24.5 MILLION DOLLAR deal with Genzyme (GENZ).
EXAS is currently working on getting a non-invasive colorectal cancer screening lab test FDA approved and to the market, but owns numerous patents in molecular diagnostics.
They just replaced their management team with the CEO and CFO from Third Wave Technologies ( creator of the HPV test ).
Third Wave was recently acquired by Hologic for $582 million last year.